MYC and diffuse large B-cell lymphoma: Whereas DLBCL without MYC translocation reveals long-term survival of 60–70% of the patients treated with combined immune-chemotherapy, DLBCL with MYC translocation – regardless of its translocation partner – shows a very poor clinical outcome [2–8].